Evidence map›Paper›PMID 42200191›Full record

ArticleNeuro-oncology advances

Imaging patterns of glioblastoma progression: Comparative analysis of sequential proton boost versus conventional photon therapy.

Ludwig Singer, Hanna Gött, Viet Duc Vu, Rita Engenhart-Cabillic, Fabian Eberle, Hildegard Dohmen, Alexandra Jensen, Stefan Lang, Marco Stein, Eberhard Uhl and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ludwig SingerDepartment of Neuroradiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0009-0001-7817-4823
Hanna GöttDepartment of Neurosurgery, Eberhard Karls University, Tübingen, Germany.
Viet Duc VuDepartment of Diagnostic and Interventional Radiology, University Hospital Giessen, Justus Liebig University, Giessen, Germany.
Rita Engenhart-CabillicDepartment of Radiation Oncology, University Hospital Marburg, Philipps-Universität Marburg, Germany; Marburg Ion-Beam Therapy Center (MIT), Germany.
Fabian EberleDepartment of Radiation Oncology, University Hospital Marburg, Philipps-Universität Marburg, Germany; Marburg Ion-Beam Therapy Center (MIT), Germany.
Hildegard DohmenInstitute of Neuropathology, University Hospital Giessen, Justus Liebig University, Giessen, Germany.
Alexandra JensenDepartment of Radiation Oncology, University Hospital Giessen, Justus Liebig University, Giessen, Germany.
Stefan LangDepartment of Neuroradiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Marco SteinDepartment of Neurosurgery, University Hospital Giessen, Justus Liebig University, Giessen, Germany, (H.G., M.S., E.U.).
Eberhard UhlDepartment of Neurosurgery, University Hospital Giessen, Justus Liebig University, Giessen, Germany, (H.G., M.S., E.U.).
Arnd DörflerDepartment of Neuroradiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Tobias StruffertDepartment of Neuroradiology, University Hospital Giessen, Justus Liebig University, Giessen, Germany.
Manuel Alexander SchmidtDepartment of Neuroradiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioblastoma is the most aggressive brain tumor, with a 5-year survival rate of only 8%. Radiotherapy plays a crucial role in multimodal treatment. With novel therapy approaches emerging, we evaluated specific imaging patterns of progression in patients treated with a sequential proton boost after standard radiochemotherapy. Methods: We analyzed data from 144 patients with histologically confirmed glioblastoma (CNS-WHO grade4), 94 received a sequential proton boost, and 50 underwent conventional photon radiation. Tumor progression (TP) was confirmed histologically or according RANO criteria. MRI segmentation was automated using CE-marked AI software, tumor voxels were classified by location (inside or outside the clinical target volume [CTV]) and CBV-perfusion status (inclusion-zone). Results: At progression, the proton group showed significantly larger contrast-enhancing tumor volumes outside the CTV ( Conclusion: Sequential proton boost therapy was associated with a distinct spatial pattern of radiographic progression, characterized by increased contrast enhancement beyond the CTV, especially in the CTV-PTV-transition-zone, without a corresponding rise in metabolic activity. These findings are hypothesis-generating and may reflect radiobiological range-edge effects or treatment-related tissue responses rather than true TP. Prospective studies integrating dosimetric and metabolic data are warranted to elucidate underlying mechanisms.

Indexed as

AIautomated tumor segmentationglioblastomaperfusion weighted imagingproton therapy

Identifiers

PMID42200191
PMCPMC13199058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.